In Phase II clinical trials (MHRA 21313/0007), Siltuximab showed significant reductions in IL6, CCL2, CXCL12, and VEGF levels, leading to decreased angiogenesis and macrophage infiltration, further validating the potential of Siltuximab in altering the tumor microenvironment. Here, IL6 is linked to neoplasm.